Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.38 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | GLB1 | P16278 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.32 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.32 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8331439 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL12319866 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL3150867 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL11982563 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL16561907 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL7129056 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL12902303 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL12301979 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL19129783 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 | |
| SCHEMBL16040788 | 1.00 | PI4KA (0.38) | PI4KAPI4K2BPI4K2API4KBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024075025-A1 | AN INDUSTRIAL PROCESS FOR THE PREPARATION OF SUBSTANTIALLY PURE 2,3-O-ISOPROPYLIDENE-D-RIBOFURANOSE | HIKAL LIMITED (IN) | 2024-04-11 | — | — | WO | claimed |
| EP-0528044-B1 | Process for producing 4-substituted gamma- lactone, and the so produced novel substances. | JAPAN TOBACCO INC (JP) | 1997-08-13 | — | — | EP | claimed |
| US-5374744-A | Sex pheronome of Japanese beetle, cupreous chafers; oxidation, reduction, cleavage, cyclization, alkynylation, hydrolysis | JAPAN TOBACCO INC. (JP) | 1994-12-20 | — | — | US | claimed |
| EP-0528044-A1 | PROCESS FOR PRODUCING 4-SUBSTITUTED $g(g)-LACTONE, AND NOVEL SUBSTANCE | JAPAN TOBACCO INC. (JP) | 1993-02-24 | — | — | EP | claimed |
| JP-5230047-A | — | — | None | — | — | JP | disclosed |
| JP-7228549-A | — | — | None | — | — | JP | disclosed |
| US-20260132144-A1 | METHOD FOR SYNTHESIS OF DIAZABICYCLO[6.2.0]DECANE RELATED COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-05-14 | — | — | US | disclosed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | AVILAR THERAPEUTICS, INC. (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4674481-A2 | CD73 INHIBITORS | Oric Pharmaceuticals, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250368677-A1 | CD73 INHIBITORS | ORIC PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-12465647-B2 | 1′-alkyl modified ribose derivatives and methods of use | SANEGENE BIO USA INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-4681936-A | Preparation of sugar ketals | BASF AKTIENGESELLSCHAFT (DE) | 1987-07-21 | — | — | US | disclosed |
| EP-0191464-A2 | Method for the preparation of sugar acetals | BASF Aktiengesellschaft (DE) | 1986-08-20 | — | — | EP | disclosed |
| EP-0076118-B1 | PROCESS FOR THE PRODUCTION OF SUGAR KETALS | Takeda Chemical Industries, Ltd. (JP) | 1985-09-04 | — | — | EP | disclosed |
| US-4464530-A | Process for production of sugar ketals | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-08-07 | — | — | US | disclosed |
| US-4460767-A | COPPER COMPOUND, CHLORIDE OR BROMIDE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1984-07-17 | — | — | US | disclosed |
| EP-0091223-A1 | Process for production of sugar ketals | Takeda Chemical Industries, Ltd. (JP) | 1983-10-12 | — | — | EP | disclosed |
| US-4096321-A | Process to produce oxazinomycin and intermediates | HOFFMANN-LA ROCHE INC. (US) | 1978-06-20 | — | — | US | disclosed |
| US-3998999-A | Process for preparing pyrazomycin and pyrazomycin B | HOFFMANN-LA ROCHE INC. (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368677-A1 | CD73 INHIBITORS | ENTPD5, NT5E, ENTPD1 | PI4KA 1205/4885PI4K2B 2063/4885PI4K2A 1875/4885 |
| US-20260083851-A1 | POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS | ASGR1, FCGR2A, FCGR3B | PI4KA 3753/4885PI4K2B 3158/4885PI4K2A 3633/4885 |
| US-12465647-B2 | 1′-alkyl modified ribose derivatives and methods of use | PARP1, PARP2, PARP11 | PI4KA 3600/4885PI4K2B 3362/4885PI4K2A 3547/4885 |
| US-20260132144-A1 | METHOD FOR SYNTHESIS OF DIAZABICYCLO[6.2.0]DECANE RELATED COMPOUNDS | CYP2C9, ODC1, AOC2 | PI4KA 807/4885PI4K2B 543/4885PI4K2A 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.